Coherus BioSciences Inc (NAS:CHRS)
$ 1.88 -0.03 (-1.57%) Market Cap: 215.68 Mil Enterprise Value: 440.51 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 42/100

Coherus BioSciences Inc at Jefferies London Healthcare Conference Transcript

Nov 21, 2019 / 09:20AM GMT
Release Date Price: $18.49 (-3.95%)
Unidentified Analyst

Good morning, everyone. Thanks for coming. Very close to the action here. (inaudible) analyst at Jefferies, and we're delighted to have with us Denny Lanfear, Founder (inaudible) the guy who brings in all the revenue. (inaudible) access. We're going to do a fireside chat, which is a great way to get us going forward.

So Denny and Jim, welcome. Thanks for coming to London.

Dennis M. Lanfear
Coherus BioSciences, Inc. - Chairman, President & CEO

Thank you for having us.

Questions & Answers

Unidentified Analyst

So let's start to talk. So after a period of debate, lots of work on the regulatory front, sorting out patent litigation, biosimilars have finally arrived in the U.S. It seems like we've been talking about them forever. Obviously, Coherus has executed really well on your initial opportunity, which competes in the $4 billion Neupogen market. Can you, Denny, give us an update on where Coherus is now? You launched UDENYCA in January, and it's done really well, posting Q3 sales well

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot